Flora Growth expands German cannabis presence with Curaleaf agreement, parallel import business | How to buy Skittles Moonrock online

Learn where to buy weed online. TOP QUALITY GRADE A++

Cannabyss Inc. is the best place online to buy top quality weed, cannabis, vape, marijuana and CBD products. Get your borderless orders delivered at the pickup spot with ease. Top Grade products for client satisfaction.

👉 Click here to Visit our shop! 🛒

Flora Growth Corp. (NASDAQ: FLGC) on Wednesday said it signed an agreement with Curaleaf Holdings Inc. (TSX: CURA) to distribute medical cannabis products in Germany, which expanded its market earlier this year.

The deal will allow Flora to import Curaleaf’s medical strains through its EU-GMP certified facility, according to a company news release.

“We are eager to partner with Curaleaf to bring their premium cannabis products to the German market,” Flora Growth Chairman and CEO Clifford Starke said in a statement.

Germany’s medical cannabis sales are expected to hit $450 million in 2024, and the legal market could reach $4.6 billion by 2034, according to data from Prohibition Partners and The Niche Research cited by Flora.

Separately, Flora is launching a parallel import business in Germany and the European Union to provide pharmaceuticals “at competitive prices.” The company tapped Manfred Ziegler, former managing director of CC Pharma, to lead the new unit.

“Our vision is to become a market leader in the European pharmaceutical and medical cannabis market,” Starke said. “Our current access to an extensive distribution network of German pharmaceuticals represents the perfect platform to launch the PI Business.”

Germany’s parallel import market, including exports, is close to $4 billion with 47% of exports to the EU originating from Germany, according to data from the European Affordable Medicines association cited by the firm.

Flora previously said it plans to focus on Germany after the firm bought TruHC in April to give it EU-GMP certified production capabilities.

The moves come as multicountry operator Curaleaf (TSX: CURA) (OTCQX: CURLF) is increasingly planting stakes abroad, especially when it comes to building brand recognition and drive prescriptions in Europe.

CEO Matt Darin told investors in May that Germany’s medical cannabis patient growth had exceeded hopes since reforms took effect, though other industry players already tempered their expectations for the nascent market. The company projected its international revenue projections to reach $100 million in 2024.

While Flora’s revenue fell 27% year-over-year in its second quarter, mostly due to slumps at its JustCBD brand, the company has been focused on its European expansion to drive future growth.